Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD

被引：16

作者：

Duchow, Ankelien ^{[1
,2
,3
,4
,5
]}

Bellmann-Strobl, Judith ^{[1
,2
,3
,4
,5
]}

Friede, Tim ^{[6
]}

Aktas, Orhan ^{[7
]}

Angstwurm, Klemens ^{[8
]}

Ayzenberg, Ilya ^{[9
]}

Berthele, Achim ^{[10
]}

Dawin, Eva ^{[11
]}

Engels, Daniel ^{[12
]}

Fischer, Katinka ^{[7
]}

Flaskamp, Martina ^{[10
]}

Giglhuber, Katrin ^{[10
]}

Grothe, Matthias ^{[13
]}

Havla, Joachim ^{[12
]}

Huemmert, Martin W. ^{[14
]}

Jarius, Sven ^{[15
]}

Kaste, Matthias ^{[16
]}

Kern, Peter ^{[17
]}

Kleiter, Ingo ^{[18
]}

Klotz, Luisa ^{[11
]}

Korporal-Kuhnke, Mirjam ^{[15
]}

Kraemer, Markus ^{[7
,19
]}

Krumbholz, Markus ^{[20
,21
,22
]}

Kuempfel, Tania ^{[12
]}

Lohmann, Lisa ^{[11
]}

Ringelstein, Marius ^{[7
,23
]}

Rommer, Paulus ^{[24
,25
]}

Schindler, Patrick ^{[1
,2
,3
,4
,5
]}

Schubert, Charlotte ^{[26
,27
,28
]}

Schwake, Carolin ^{[9
]}

Senel, Makbule ^{[29
]}

Then Bergh, Florian ^{[30
]}

Tkachenko, Daria ^{[14
]}

Tumani, Hayrettin ^{[29
]}

Trebst, Corinna ^{[14
]}

Vardakas, Ioannis ^{[29
]}

Walter, Annette ^{[31
]}

Warnke, Clemens ^{[32
,33
]}

Weber, Martin S. ^{[34
,35
]}

Wickel, Jonathan ^{[36
]}

Wildemann, Brigitte ^{[15
]}

Winkelmann, Alexander ^{[25
]}

Paul, Friedemann ^{[1
,2
,3
,4
,5
]}

Stellmann, Jan-Patrick ^{[26
,27
,28
,37
,38
]}

Haeussler, Vivien ^{[26
,27
,28
,39
,40
,41
]}

机构：

[1] Charite Univ Med Berlin, Neurosci Clin Res Ctr, Berlin, Germany

[2] Charite Univ Med Berlin, Expt & Clin Res Ctr, Berlin, Germany

[3] Free Univ Berlin, Berlin, Germany

[4] Humboldt Univ, Berlin, Germany

[5] Max Delbruck Ctr Mol Med Helmholtz Assoc MDC, Berlin, Germany

[6] Univ Med Ctr Gottingen, Dept Med Stat, Gottingen, Germany

[7] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany

[8] Univ Regensburg, Dept Neurol, Regensburg, Germany

[9] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany

[10] Tech Univ Munich, Sch Med, Dept Neurol, Klinikum Rechts Isar, Munich, Germany

[11] Univ Munster, Dept Neurol, Inst Translat Neurol, Munster, Germany

[12] Ludwig Maximilians Univ Munchen, LMU Hosp, Inst Clin Neuroimmunol, Munich, Germany

[13] Univ Greifswald, Dept Neurol, Greifswald, Germany

[14] Hannover Med Sch, Dept Neurol, Hannover, Germany

[15] Heidelberg Univ, Dept Neurol, Mol Neuroimmunol Grp, Heidelberg, Germany

[16] Nordwest Hosp Sanderbusch, Dept Neurol, Sande, Germany

[17] Asklepios Expert Clin Teupitz, Dept Neurol, Teupitz, Germany

[18] Behandlungszentrum Kempfenhausen Multiple Skleros, Marianne Strauss Klin, Berg, Germany

[19] Alfried Krupp Hosp, Dept Neurol, Essen, Germany

[20] Univ Hosp, Multiple Sclerosis Ctr, Ctr Translat Med, Dept Neurol & Pain Treatment,Brandenburg Med Sch, Rudersdorf, Germany

[21] Brandenburg Med Sch Theodor Fontane, Fac Hlth Sci Brandenburg, Rudersdorf, Germany

[22] Univ Hosp Tubingen, Dept Neurol & Stroke, Tubingen, Germany

[23] Heinrich Heine Univ Dusseldorf, Ctr Neurol & Neuropsychiat, Dept Neurol, LVR Klinikum, Dusseldorf, Germany

[24] Med Univ Vienna, Dept Neurol, Vienna, Austria

[25] Rostock Univ Med Ctr, Dept Neurol, Rostock, Germany

[26] Univ Med Ctr Hamburg Eppendorf, Dept Neurol, Hamburg, Germany

[27] Univ Med Ctr Hamburg Eppendorf, Inst Neuroimmunol, Hamburg, Germany

[28] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[29] Univ Ulm, Dept Neurol, Ulm, Germany

[30] Univ Leipzig, Dept Neurol, Leipzig, Germany

[31] Herford Hosp, Dept Neurol, Herford, Germany

[32] Univ Cologne, Fac Med, Dept Neurol, Cologne, Germany

[33] Univ Hosp Cologne, Gottingen, Germany

[34] Univ Med Ctr Gottingen, Inst Neuropathol, Dept Neurol, Gottingen, Germany

[35] Fraunhofer Inst Translat Med & Pharmacol, Jena, Germany

[36] Jena Univ Hosp, Dept Neurol, Sect Translat Neuroimmunol, Hamburg, Germany

[37] Hop La Timone, APHM, CEMEREM, Marseille, France

[38] Aix Marseille Univ, CNRS, CRMBM, Marseille, France

[39] Univ Med Ctr Hamburg Eppendorf, Dept Neurol, Eppendorf 52, D-20251 Hamburg, Germany

[40] Univ Med Ctr Hamburg Eppendorf, Eppendorf 52, D-20251 Hamburg, Germany

[41] Univ Med Ctr Hamburg Eppendorf, Inst Neuroimmunol, Eppendorf 52, D-20251 Hamburg, Germany

来源：

ANNALS OF NEUROLOGY | 2024年 / 95卷 / 04期

关键词：

OPTICA SPECTRUM DISORDER; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS-OPTICA; DIAGNOSTIC-CRITERIA; MULTIPLE-SCLEROSIS; MULTICENTER; IGG; PREDICTORS; EFFICACY; FEATURES;

D O I：

10.1002/ana.26858

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Objective: To investigate accumulation of disability in neuromyelitis optica spectrum disorder (NMOSD) and myelin oligodendrocyte glycoprotein-antibody-associated disease (MOGAD) in a changing treatment landscape. We aimed to identify risk factors for the development of disability milestones in relation to disease duration, number of attacks, and age.Methods: We analyzed data from individuals with NMOSD and MOGAD from the German Neuromyelitis Optica Study Group registry. Applying survival analyses, we estimated risk factors and computed time to disability milestones as defined by the Expanded Disability Status Score (EDSS).Results: We included 483 patients: 298 AQP4-IgG(+) NMOSD, 52 AQP4-IgG(-)/MOG-IgG(-) NMOSD patients, and 133 patients with MOGAD. Despite comparable annualized attack rates, disability milestones occurred earlier and after less attacks in NMOSD patients than MOGAD patients (median time to EDSS 3: AQP4-IgG+ NMOSD 7.7 (95% CI 6.6-9.6) years, AQP4-IgG(-)/MOG-IgG(-) NMOSD 8.7) years, MOGAD 14.1 (95% CI 10.4-27.6) years; EDSS 4: 11.9 (95% CI 9.7-14.7), 11.6 (95% lower CI 7.6) and 20.4 (95% lower CI 14.1) years; EDSS 6: 20.1 (95% CI 16.5-32.1), 20.7 (95% lower CI 11.6), and 37.3 (95% lower CI 29.4) years; and EDSS 7: 34.2 (95% lower CI 31.1) for AQP4-IgG(+) NMOSD). Higher age at onset increased the risk for all disability milestones, while risk of disability decreased over time.Interpretation: AQP4-IgG(+) NMOSD, AQP4-IgG(-)/MOG-IgG(-) NMOSD, and MOGAD patients show distinctive relapse-associated disability progression, with MOGAD having a less severe disease course. Investigator-initiated research has led to increasing awareness and improved treatment strategies appearing to ameliorate disease outcomes for NMOSD and MOGAD.ANN NEUROL 2024

引用

页码：720 / 732

页数：13

共 48 条

[1] Relapse activity in the chronic phase of anti-myelin-oligodendrocyte glycoprotein antibody-associated disease
Akaishi, Tetsuya
Misu, Tatsuro
Fujihara, Kazuo
Takahashi, Toshiyuki
Takai, Yoshiki
Nishiyama, Shuhei
Kaneko, Kimihiko
Fujimori, Juichi
Ishii, Tadashi
Aoki, Masashi
Nakashima, Ichiro
[J]. JOURNAL OF NEUROLOGY, 2022, 269 (06) : 3136 - 3146
[2] Long-term Outcomes in Patients With Myelin Oligodendrocyte Glycoprotein Immunoglobulin G-Associated Disorder
不详
[J]. JAMA NEUROLOGY, 2020, 77 (12) : 1575 - 1577
[3] Pain, Depression, and Quality of Life in Neuromyelitis Optica Spectrum Disorder A Cross-Sectional Study of 166 AQP4 Antibody-Seropositive Patients
Ayzenberg, Ilya
Richter, Daniel
Henke, Eugenia
Asseyer, Susanna
Paul, Friedemann
Trebst, Corinna
Huemmert, Martin W.
Havla, Joachim
Kuempfel, Tania
Ringelstein, Marius
Aktas, Orhan
Wildemann, Brigitte
Jarius, Sven
Haussler, Vivien
Stellmann, Jan-Patrick
Senel, Makbule
Klotz, Luisa
Pellkofer, Hannah L.
Weber, Martin S.
Pawlitzki, Marc
Rommer, Paulus S.
Berthele, Achim
Wernecke, Klaus-Dieter
Hellwig, Kerstin
Gold, Ralf
Kleiter, Ingo
[J]. NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (03): : E985
[4] Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria
Banwell, Brenda
Bennett, Jeffrey L.
Marignier, Romain
Kim, Ho Jin
Brilot, Fabienne
Flanagan, Eoin P.
Ramanathan, Sudarshini
Waters, Patrick
Tenembaum, Silvia
Graves, Jennifer S.
Chitnis, Tanuja
Brandt, Alexander U.
Hemingway, Cheryl
Neuteboom, Rinze
Pandit, Lekha
Reindl, Markus
Saiz, Albert
Sato, Douglas Kazutoshi
Rostasy, Kevin
Paul, Friedemann
Pittock, Sean J.
Fujihara, Kazuo
Palace, Jacqueline
[J]. LANCET NEUROLOGY, 2023, 22 (03) : 268 - 282
[5] Clinical characteristics of very late-onset neuromyelitis optica spectrum disorder
Cai, L. J.
Zhang, Q.
Zhang, Y.
Chen, H. X.
Shi, Z. Y.
Du, Q.
Zhou, H. Y.
[J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
[6] Characterization of neuromyelitis optica and neuromyelitis optica spectrum disorder patients with a late onset
Collongues, N.
Marignier, R.
Jacob, A.
Leite, M. I.
Sivas, A.
Paul, F.
Zephir, H.
Akman-Demirs, G.
Elsone, L.
Jarius, S.
Papeix, C.
Mutch, K.
Saips, S.
Wildemann, B.
Kitley, J.
Karabudak, R.
Aktas, O.
Kuscu, D.
Altintas, A.
Palace, J.
Confavreux, C.
De Seze, J.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (08) : 1086 - 1094
[7] Neuromyelitis Optica in France: A Multicenter Study of 125 Patients
Collongues, Nicolas
Marignier, Romain
Zephir, Helene
Papeix, Anne Caroline
Blanc, Frederic
Ritleng, Cecile
Tchikviladze, Maia
Outteryck, Olivier
Vukusic, Sandra
Fleury, Marie
Fontaine, Bertrand
Brassat, David
Clanet, Michel
Milh, Mathieu
Pelletier, Jean
Audoin, Bertrand
Ruet, Aurelie
Frenay, Christine Lebrun
Thouvenot, Eric
Camu, William
Debouverie, Marc
Creange, Alain
Moreau, Thibault
Labauge, Pierre
Castelnovo, Giovanni
Edan, Gilles
Le Page, Emmanuelle
Defer, Gilles
Barroso, Bruno
Heinzlef, Olivier
Gout, Olivier
Rodriguez, Diana
Wiertlewski, Sandrine
Laplaud, David
Borgel, Florent
Tourniaire, Patricia
Grimaud, Jerome
Brochet, Bruno
Vermersch, Patrick
Confavreux, Christian
De Seze, Jerome
[J]. NEUROLOGY, 2010, 74 (09) : A167 - A168
[8] Relapses and progression of disability in multiple sclerosis.
Confavreux, C
Vukusic, S
Moreau, T
Adeleine, P
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (20) : 1430 - 1438
[9] Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial
Cree, Bruce A. C.
Bennett, Jeffrey L.
Kim, Ho Jin
Weinshenker, Brian G.
Pittock, Sean J.
Wingerchuk, Dean M.
Fujihara, Kazuo
Paul, Friedemann
Cutter, Gary R.
Marignier, Romain
Green, Ari J.
Aktas, Orhan
Hartung, Hans-Peter
Lublin, Fred D.
Drappa, Jorn
Barron, Gerard
Madani, Soraya
Ratchford, John N.
She, Dewei
Cimbora, Daniel
Katz, Eliezer
Shuey, Neil
Milanov, Ivan
Kaprelyan, Ara
Tarnev, Ivaylo
Haralanov, Lyubomir
Carruthers, Robert
Munoz, Mario
Quinones, Jairo
Vargas, Jose
Rodriguez, Jesus
Nytrova, Petra
Vachova, Marta
Mares, Jan
Haldre, Sulev
Gross-Paju, Katrin
Ziemssen, Tjalf
Zettl, Uwe Klaus
Klotz, Luisa
Bergh, Florian Then
Lau, Alexander
Dioszeghy, Peter
Satori, Maria
Vecsei, Laszlo
Achiron, Anat
Karni, Arnon
Vaknin-Dembinsky, Adi
Saida, Takahiko
Misu, Tatsuro
Baba, Masayuki
[J]. LANCET, 2019, 394 (10206) : 1352 - 1363
[10] Rituximab De-escalation in Patients With Neuromyelitis Optica Spectrum Disorder
Demuth, Stanislas
Collongues, Nicolas
Audoin, Bertrand
Ayrignac, Xavier
Bourre, Bertrand
Ciron, Jonathan
Cohen, Mikael
Deschamps, Romain
Durand-Dubief, Francoise
Maillart, Elisabeth
Papeix, Caroline
Ruet, Aurelie
Zephir, Helene
Marignier, Romain
De Seze, Jerome
[J]. NEUROLOGY, 2023, 101 (04) : E438 - E450

← 1 2 3 4 5 →